Wakefit grants 3.28 lakh ESOPs at Re 1
Wakefit Innovations granted 3,28,342 Employee Stock Options under its 2019 plan, approved by the Nomination and Remuneration Committee on May 23, 2026. The options, exercisable into equity shares with a face value of Re. 1, have an exercise price of Re. 1. Vesting begins after 12 months and extends up to 5 years, subject to performance and continued service.

*this image is generated using AI for illustrative purposes only.
Wakefit Innovations has granted 3,28,342 Employee Stock Options under its Wakefit Employee Stock Option Plan - 2019 (ESOP 2019). The grant was approved by the company's Nomination and Remuneration Committee on May 23, 2026, in compliance with SEBI regulations.
Grant Details
The options are exercisable into 3,28,342 equity shares, each with a face value of Re. 1. The exercise price has been determined at Re. 1 per option. The vesting for these options will commence after a minimum period of 12 months from the grant date and will not extend beyond 5 years. Vesting is contingent upon time and performance criteria, subject to the employee's continued service with the organization.
Key Terms
The following table outlines the specific details of the grant:
| Particulars | Details |
|---|---|
| Options Granted | 3,28,342 |
| Exercise Price | Re. 1 per Option |
| Vesting Period | 12 months to 5 years |
| Exercise Window | 1 year from vesting date |
All vested options must be exercised within a maximum period of one year from the date of vesting. The company noted that the vesting timelines may be extended for employees on unauthorized or non-statutory leaves as per the ESOP Plan provisions.
Historical Stock Returns for Wakefit Innovations
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.82% | -11.32% | -9.95% | -33.46% | -33.46% | -33.46% |
How will this ESOP grant impact Wakefit's employee retention and talent acquisition strategy in the competitive sleep-tech market?
What are the potential implications for Wakefit's equity dilution and shareholder value as these options vest over the next five years?
Could this move signal Wakefit's preparations for an IPO or a significant funding round in the near future?


































